Effect of 4-hydroxynonenal, a product of lipid peroxidation, on NK susceptibility of human K562 target cells

Anticancer Research

Volumn 18, Issue 5 A, 1998, Pages 3591-3595

  Rinaldi, Monica ^a,c   Tricarico, Maria ^a   Bonmassar, Enzo ^a,b   Parrella, Paola ^a,d   Barrera, Giuseppina ^e   Fazio, Vito Michele ^a,c  

^a CNR   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^d CATHOLIC UNIVERSITY   (Italy)

^e UNIVERSITY OF TURIN   (Italy)

Author keywords

HNE; Leukemic cell; NK

Indexed keywords

4 HYDROXYNONENAL; BETA INTERFERON; HEMIN;

ARTICLE; CELL STRAIN K 562; CYTOLYSIS; CYTOTOXICITY; GROWTH INHIBITION; HUMAN; HUMAN CELL; MONONUCLEAR CELL; NATURAL KILLER CELL; PRIORITY JOURNAL; TARGET CELL;

ALDEHYDES; CELL DIVISION; CYSTEINE PROTEINASE INHIBITORS; HUMANS; IMMUNOTHERAPY; INTERFERONS; K562 CELLS; KILLER CELLS, LYMPHOKINE-ACTIVATED; KILLER CELLS, NATURAL;

EID: 0031730994     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Esterbauer H: Aldehydic products of lipid peroxidation In: Free Radicals, Lipid Peroxidation and Cancer (McBrien D.H.C. and Slater T.F. eds). Academic press, 1982, pp 101-125.
2. Frei B, Forte TM, Ames BN and Cross CE: Gas phase oxidants of cigarette smoke induce lipid peroxidation and changes in lipoprotein properties in human blood plasma. Protective effects of ascorbic acid. Biochem J 277: 133-138,1991.
3. Hoff HF and O'Neil JA: Oxidation of LDL: role in atherogenesis. Klin-Wochenschr 69: 1032-1038,1991.
4. Fazio VM, Rinaldi M, Ciafrè S, Barrera G and Farace MG: Control of neoplastic cell proliferation and differentiation by restoration of 4-hydroxynonenal physiological concentrations. Molec Aspects Med 14: 217-228, 1993.
5. Cheeseman KH, Collins M, Maddix S, Milia A, Proudfoot K, Slater TF, Burton GW, Webb A and Ingold KU: Lipid peroxidation in regenerating rat liver. FEBS Lett 209: 191-196, 1986.
6. Masotti L, Casali E and Galeotti T: Lipid peroxidation in tumor cells. Free Radical Biol Med 4: 377-386, 1988.
7. Dianzani MU, Poli G, Canuto RA, Rossi MA , Biocca ME , Biasi F, Cecchini G, Muzio G, Ferro M and Esterbauer H: New data on kinetics of lipid peroxidation in experimental hepatomas and preneoplastic nodules. Toxicol Pathol 14: 404-410, 1986.
8. Borrello S, Minotti G, Palombini G , Grattagliano A and Galeotti T: Superoxide-dependent lipid peroxidation and vitamin E content of microsomes from hepatomas with different growth rate. Arch Biochem Biophys 238: 588-595, 1985.
9. Fazio VM, Barrera G, Martinotti S, Farace MG, Giglioni B, Frati L, Manzari V and Dianzani MU: 4-hydroxy-nonenal, a product of cellular lipid peroxidation, which modulates c-myc and globin gene expression in K562 cells. Cancer Res 52: 4866-4871, 1992.
10. Chomienne C, Ballerini P, Balitrand N, Amar M, Bernard JF, Boivin P, Daniel MT, Berger R, Castaigne S and Degos L: Retinoic acid therapy for promyelocytic leukemia. Lancet Sept 23:746-747, 1989.
11. Galeotti T, Masotti L, Borrello S and Casali E: Oxy-radical metabolism and control of tumor growth. Xenobiotica 21: 1041-1051, 1991.
12. Esterbauer H, Zollner H and Schaur RJ In: Membrane lipid oxidation (Vigo Pelfrey, C., Ed.), Boca Raton FL, CRC Press, 1990, pp.240-268.
13. Poli G, Dianzani MU, Cheeseman K, Slater TF, Lang J and Esterbauer H: Separation and characterization of the aldehydic products of lipid peroxidation stimulated by carbon tetrachloride or ADP-iron in isolated rat liver hepatocytes and rat liver microsomal suspension. Biochem J 227: 629-683, 1985.
14. Esterbauer H: Lipid peroxidation products: formation, chemical properties and biological activities. In: Free Radicals in liver injury (Poli G., Cheeseman K.H, Dianzani M.U. and Slater T.F.,eds) IRL press, 1985, pp 29-47.
15. Esterbauer H, Zollner H and Schaur RJ:Hydroxyalkenals: cytotoxic products of lipid peroxidation. In ISI Atlas of Science: Biochemistry, 1988.
16. Esterbauer H, Schauer RJ and Zollner H: Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic Biol Med 11: 81-128,1991.
17. Barrera G, Di Mauro C, Muraca R, Ferrero D, Cavalli G, Fazio VM, Paradisi L and Dianzani M U: Induction of Differentiation in Human HL-60 Cells by 4-Hydroxynonenal, a Product of Lipid Peroxidation. Exp Cell Res 197: 148-152, 1991.
18. Barrera G, Brossa O, Fazio VM, Farace MG, Paradisi L, Gravela E and Dianzani MU:Effects of 4-hydroxynonenal, a product of lipid peroxidation, on cell proliferation and ornithine decarboxylase activity. Free Rad Res Comms 14: 81-89, 1991.
19. Gidlund M, Orn A, Patengale PK, Jansson M, Wigzell H and Nilsson K: Natural Killer cells kill tumor cells at a given stage of differentiation. Nature (Lond) 292, 848-850, 1981
20. Stern P, Gidlund M, Orn A and Wigzell H: Natural killer cells mediate lysis of embryonal carcinoma cell lacking MHC. Nature (Lond) 285: 341-342, 1980
21. Di Mauro C, Cavalli G, Amprimo MC, Paradisi L, Scano G, Curzio M and Dianzani MU: Cell Biochem Func 8: 147-155, 1990.
22. Boyum A: Isolation of lymphocytes from human blood. Further observation. J Clin Lab Invest 21: 31-34, 1968.
23. Lozzio C.B, Lozzio BB: Properties and usefulness of the original K562 human myelogenous leukemia cell line. Leuk Res 3: 363-369, 1979.
24. Barrera G, Biasi F, Fazio VM, Paradisi L and Dianzani MU: Repeated treatments with a low concentration affect K562 cell proliferation. Chemical Carcinogenesis, 1991.
25. Silva A, Bonavida B, Targan S: Mode of action of interferon-mediated modulation of natural killer cytotoxic activity: recruitment of pre-NK cells and enhanced kinetics of lysis. J Immunol 125: 479-482, 1980.
26. Wright SC and Bonavida B: Studies on the mechanism of natural killer (NK) cell-mediated cytotoxicity. III Interferon-pretreatment of effector cell augments the lytic activity of natural killer cytotoxic factors (NKCF). J Immunol 130: 2960-2964, 1983.
27. Ortaldo JRand Herberman RB: Augmentation of natural killer activity. In: Immunobiology of natural killer cells. (Lotzova E. and Herberman R.B. eds), Boca Raton CRC Press, 1986, vol. I, pp.145-162.
28. Beug H, Blundell PA and Graff T: Reversibility of differentiation and proliferative capacity in avian myelomonocytic cells transformed by E26 leukemia cells. Genes Devel 1 : 277-, 1987.
29. Brinster RL: The effects of cells transferred into the mouse blastocyst on subsequent development. J Exp Med 140:1049-1056, 1974.
30. De Cosse JJ, Gossens CL and Cuzma JF: Breast cancer: introduction of differentiation by embryonic tissue. Science 181: 1057-1058, 1973.
31. Gootwine E, Webb C and Sachs L: Participation of myeloid leukemia cells injected into embryos in hematopoietic differentiation in adult mice. Nature 299: 63-65, 1982.
32. Pierce GB and Speers WC: Tumor as caricatures of the process of tissue renewal: prospects for therapy by directing differentiation. Cancer Res 48: 1966-2004, 1988.
33. Sachs L: Growth, differentiation and the reversal of malignancy. Sci Am 254: 40-47, 1986.
34. Dmitrovsky E, Markman M and Marks PA: Clinical use of differentiating agents in cancer therapy. In: Cancer therapy; Cancer Chemotherapy and Biological Response Modifiers, Annual 11 (Pinedo HM, Chabner BA and Longo DL, eds). Amsterdam-New York, Elsevier Science Publishers, 1990.
35. Yen A., Freeman L. and Fishbaugh J., Leukemia Res 11: 63, 1987.
36. Marks PA and Rifkind RA: Differentiating agents in cancer therapy. In: Cancer Therapy; Cancer Chemotherapy and Biological Response Modifiers, Annual 11. Pinedo HM, Longo DL and Chabner BA, eds), Elsevier Science Publishers, 1991.
37. Francis GE and Cunningham JM: Growth and differentiation control. In: Cancer therapy; Cancer Chemotherapy and Biological Response Modifiers, Annual 11 (Pinedo H.M., Chabner B.A. and Longo D.L., eds), Elsevier Science Publishers, 1990.